Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Weighted Average and Diluted) (2016 - 2023)

Historic EPS (Weighted Average and Diluted) for RedHill Biopharma (RDHL) over the last 9 years, with Q2 2022 value amounting to $0.02.

  • RedHill Biopharma's EPS (Weighted Average and Diluted) fell 6666.67% to $0.02 in Q2 2022 from the same period last year, while for Jun 2022 it was $0.19, marking a year-over-year decrease of 2083.33%. This contributed to the annual value of $0.01 for FY2023, which is 10833.33% up from last year.
  • Latest data reveals that RedHill Biopharma reported EPS (Weighted Average and Diluted) of $0.02 as of Q2 2022, which was down 6666.67% from $0.06 recorded in Q2 2021.
  • In the past 5 years, RedHill Biopharma's EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q2 2021 and a low of $0.02 during Q2 2022
  • In the last 3 years, RedHill Biopharma's EPS (Weighted Average and Diluted) had a median value of $0.05 in 2018 and averaged $0.04.
  • As far as peak fluctuations go, RedHill Biopharma's EPS (Weighted Average and Diluted) plummeted by 1666.67% in 2018, and later tumbled by 6666.67% in 2022.
  • RedHill Biopharma's EPS (Weighted Average and Diluted) (Quarter) stood at $0.05 in 2018, then increased by 20.0% to $0.06 in 2021, then tumbled by 66.67% to $0.02 in 2022.
  • Its EPS (Weighted Average and Diluted) stands at $0.02 for Q2 2022, versus $0.06 for Q2 2021 and $0.05 for Q2 2018.